Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model

Cancer Research

Volumn 60, Issue 20, 2000, Pages 5714-5722

  Miller, Cathie G ^a   Fraser, Nigel W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; VIRUS ATTENUATION;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; INJECTIONS, INTRAVENTRICULAR; KILLER CELLS, NATURAL; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED DBA; MICE, SCID; NEOPLASM TRANSPLANTATION; VACCINES, ATTENUATED;

EID: 0034667441     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant
2. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors
3. Treatment of malignant gliomas using ganciclovir hypersensitive, ribonucleaotide reductase deficient herpes simplex viral mutant
4. The incidence of complement-fixing antibodies to herpes simplex and herpes-like viruses in man and rhesus monkeys
5. Control of acute cutaneous herpes simplex virus infection: T cell-mediated viral clearance is dependent upon interferon-γ (IFN-γ)
6. Immune cell infiltration in corneas of mice with recurrent herpes simplex virus disease
7. The role of immune mechanisms in control of herpes simplex virus infection of the peripheral nervous system
8. Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: Implications for the fate of vitally infected neurons
9. Macrophages and other nonspecific defenses: Role in modulating resistance against herpes simplex virus
10. The role of antibody in herpes simplex virus infection in humans
11. The role of T cell immunity in control of herpes simplex virus
12. Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type I corneal infection
13. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease
14. Cell-mediated immunity to herpes simplex virus: Specificity of cytotoxic T cells
15. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1
16. γ-Interferon expression during acute and latent nervous system infection by herpes simplex virus type 1
17. Increased levels of IFN-γ in the trigeminal ganglion correlate with protection against HSV-1-induced encephalitis following subcutaneous administration with androstenediol
18. Cytokine production in the nervous system of mice during acute and latent infection with herpes simplex virus type 1
19. Increased interleukin-10 serum levels in patients with solid tumours
20. Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: Neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors
21. Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages
22. Establishment of four functional, clonal strains of animal cells in culture
23. Investigation of herpes simplex virus type I genes encoding multiply inserted membrane proteins
24. Detection of herpes simplex type 1 transcripts during latent infection in mice
25. Neurons derived from a human teratocarcinoma cell line establishes molecular and structural polarity following transplantation into the rodent brain
26. In vivo and in vitro models of medulloblastomas and other primitive neuroectodermal brain tumors of childhood
27. Treatment of experimental subcutaneous human melanoma with a replication restricted herpes simplex virus mutant
28. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant
29. Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS
30. Herpes simplex 1716, an ICP34.5 mutant, is severly replication restricted in human skin xenografts in vivo
31. Different roles for L3T4+ and Lyt 2+ T cell subsets in the control of an acute herpes simplex virus infection of the skin and nervous system
32. Antiviral activity of interferon in rats and the effect of immune suppression
33. HSV-1 infection and immunity in immunosuppressed mice
34. Effect of immunization and immunosuppression on induced ocular shedding and recovery of herpes simplex virus in infected rabbits
35. Protection against experimental cerebral metastases of murine melanoma B16 by active immunization
36. Inhibition of major histocompatibility complex class 1 antigen presentation in pig and primate cells by herpes simplex virus type 1 and 2 ICP47
37. Herpes simplex virus torns off the TAP to evade host immunity
38. A viral inhibitor of peptide transporters for antigen presentation
39. Advances in cancer immunotherapy
40. Interference with major histocompatibility complex class II-restricted antigen presentation in the brain by herpes simplex virus type 1: A possible mechanism of evasion of the immune response
41. Nervous tissue as an immune compartment: The dialect of the immune response in the CNS
42. Inflammatory cytokines in the brain: Does the CNS shape immune responses?
43. Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors
44. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity
45. The T-cell-mediated immune response of mice to herpes simplex virus
46. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer
47. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases but does not abolish gene transfer to experimental brain tumors by a HSV-1 vector
48. Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response